<i>In Vitro</i> Skin Retention of Crisaborole after Topical Application
Crisaborole, a nonsteroidal phosphodiesterase 4 inhibitor, represents the first nonsteroidal medication approved for the treatment of atopic dermatitis in over a decade. In this work, crisaborole skin permeation and retention was studied <i>in vitro</i> from a 2% ointment using porcine s...
Main Authors: | Adriana Fantini, Anna Demurtas, Sara Nicoli, Cristina Padula, Silvia Pescina, Patrizia Santi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/6/491 |
Similar Items
-
Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
by: Joseph Fowler, et al.
Published: (2023-02-01) -
Treatment of psoriasis with crisaborole
by: Erica B. Lee, et al.
Published: (2019-02-01) -
Altered Gene Expression of IL-35 and IL-36α in the Skin of Patients with Atopic Dermatitis
by: Weronika Zysk, et al.
Published: (2023-12-01) -
Novel Vehicles For Drug Delivery In Atopic Dermatitis: A Narrative Review
by: Christopher Farkouh, et al.
Published: (2023-10-01) -
Solving the health disparity of eczema assessment: A role for skin tape soluble protein?
by: Kittipos Visitsunthorn, MD, et al.
Published: (2024-02-01)